FUJIFILM Diosynth Biotechnologies Celebrates the Expansion Completion at its California Cell Therapy Facility
ATRA Stock | USD 12.15 0.83 6.39% |
About 62% of Atara Biotherapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Atara Biotherapeutics suggests that many traders are alarmed. The current market sentiment, together with Atara Biotherapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Atara Biotherapeutics stock news signals to limit their universe of possible portfolio assets.
Atara |
Celebration also includes achieving EMA regulatory issuance of GMP certification at the site FUJIFILM Diosynth Biotechnologies celebrates the expansion completion at its California cell therapy facility Ribbon cutting celebration Celebration of FUJIFILM Diosynth Biotechnologies cell therapy facility expansion opening Left to right Dave Bolish, Site Head, Karen Frost, VP Corporate Affairs, Lars Petersen, President CEO, Al Adam, Mayor, Thousand Oaks, California. THOUSAND OAKS, CALIF., Nov. 20,
Read at finance.yahoo.com
Atara Biotherapeutics Fundamental Analysis
We analyze Atara Biotherapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Atara Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Atara Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Debt
Total Debt Comparative Analysis
Atara Biotherapeutics is currently under evaluation in total debt category among its peers. Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Atara Biotherapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Atara Biotherapeutics stock to make a market-neutral strategy. Peer analysis of Atara Biotherapeutics could also be used in its relative valuation, which is a method of valuing Atara Biotherapeutics by comparing valuation metrics with similar companies.
Peers
Atara Biotherapeutics Related Equities
KPTI | Karyopharm Therapeutics | 16.67 | ||||
BTAI | BioXcel Therapeutics | 6.43 | ||||
HOOK | Hookipa Pharma | 4.86 | ||||
ALLO | Allogene Therapeutics | 0.92 | ||||
RCUS | Arcus Biosciences | 0.50 | ||||
FATE | Fate Therapeutics | 0.62 | ||||
APLS | Apellis Pharmaceuticals | 0.85 | ||||
MREO | Mereo BioPharma | 1.06 | ||||
ITOS | Iteos Therapeutics | 1.21 | ||||
XFOR | X4 Pharmaceuticals | 1.23 | ||||
TCRX | Tscan Therapeutics | 1.61 | ||||
CRBU | Caribou Biosciences | 1.76 | ||||
HRTX | Heron Therapeuti | 3.13 | ||||
SANA | Sana Biotechnology | 5.29 | ||||
ABOS | Acumen Pharmaceuticals | 5.82 |
Complementary Tools for Atara Stock analysis
When running Atara Biotherapeutics' price analysis, check to measure Atara Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atara Biotherapeutics is operating at the current time. Most of Atara Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Atara Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atara Biotherapeutics' price. Additionally, you may evaluate how the addition of Atara Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |